<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00742820</url>
  </required_header>
  <id_info>
    <org_study_id>LP-RTG-01-01</org_study_id>
    <nct_id>NCT00742820</nct_id>
  </id_info>
  <brief_title>Bioequivalence Study Comparing Calcium Acetate Oral Solution Versus Calcium Acetate Gelcaps in Healthy Volunteers</brief_title>
  <official_title>Randomized, Controlled, 3-Arm, Open Label, Cross-Over Bioequivalence Study Comparing Liquid PhosLo vs. PhosLo Gelcaps Using Calcium Citrate as a Positive Control in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fresenius Medical Care North America</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fresenius Medical Care North America</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To compare the bioequivalence of calcium acetate oral solution vs. calcium acetate gelcaps in
      healthy volunteers with calcium citrate as a positive control.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2008</start_date>
  <completion_date type="Actual">November 2008</completion_date>
  <primary_completion_date type="Actual">November 2008</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Serum Phosphate</measure>
    <time_frame>24 hrs</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Urinary Calcium</measure>
    <time_frame>24 hrs</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Serum Calcium</measure>
    <time_frame>24 hrs</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urinary Phosphate</measure>
    <time_frame>24 hrs</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum insulin and glucose</measure>
    <time_frame>6 hrs</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">46</enrollment>
  <condition>Hyperphosphatemia</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Calcium Acetate Oral Solution 667 mg per 5 mL</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Calcium Acetate 667 mg Gelcaps</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Calcium Citrate 950 mg Caplets</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Calcium Acetate Oral Solution 667 mg per 5 mL</intervention_name>
    <description>Drug: Calcium acetate oral solution 667 mg calcium acetate, USP per 5 mL (169 mg of elemental calcium per 5 mL); Dosage: 30 mL of calcium acetate oral solution; Dosage frequency: three times per day with meals; Duration: 3 days and the morning of day 4, in total ten doses</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Calcium Acetate 667 mg GelCaps</intervention_name>
    <description>Drug: PhosLo GelCaps (calcium acetate) 667 mg (169 mg of elemental calcium per gelcap); Dosage: 6 gelcaps; Dosage frequency: three times per day with meals; Duration: 3 days and the morning of day 4, in total ten doses.</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Calcium Citrate 950 mg Caplets</intervention_name>
    <description>Drug: Calcium Citrate 950 mg Caplets (200 mg of elemental calcium per caplet); Dosage: 5 caplets; Dosage frequency: three times per day with meals; Duration: 3 days and the morning of day 4, in total ten doses</description>
    <arm_group_label>3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Signed and dated informed consent form

          -  Ages: 18-75 years

          -  Serum Calcium level 8.6-10.2 mg/dL

          -  25 vitamin D level 20-100 ng/mL

          -  1, 25 dihydroxy vitamin D level 6-62 pg/mL

          -  Fasting glucose level of 65-99 mg/dL (min 8 hr fast)

          -  iPTH level of 10-65 pg/mL

          -  Serum phosphorous level of 2.5-4.5 mg/dL

          -  Albumin level of 3.6-5.1 g/dL

          -  Sodium level of 135-146 mEq/L

          -  Potassium level of 3.5-5.3 mEq/L

          -  Negative pregnancy test (at screening and prior to dosing) for women of childbearing
             potential and subjects must agree to use adequate contraception (hormonal or double
             barrier method) during the study

          -  No clinically significant abnormalities on electrocardiogram (ECG) reading as
             determined by the INVESTIGATOR

          -  No clinically significant abnormalities on liver function tests

          -  No clinically significant abnormalities on CBC and coagulation studies

          -  No clinically significant abnormalities on kidney function (eGFR using serum
             creatinine)

          -  BMI between 18.5-30

          -  Subjects must agree not to consume alcohol while in the treatment phase of the study

        Exclusion Criteria:

          -  Women who are pregnant or breast feeding

          -  Malignancy except squamous cell carcinoma of the skin

          -  Documented current acute or chronic disease

          -  Positive for human immunodeficiency virus (HIV), hepatitis B or hepatitis C

          -  Myocardial infarction within 6 months of study Day 0

          -  Parathyroidectomy within 6 months of study Day 0

          -  Gastrointestinal disorder associated with impaired absorption of oral medications

          -  Inability to swallow tablets or tolerate calcium acetate oral solution

          -  Hormonal therapy (except for contraceptives), immunotherapy or corticoid therapy

          -  Concurrent antibiotic treatment

          -  Any concurrent investigational treatment within 30 days of screening

          -  Unable or unwilling to comply fully with the protocol

          -  Diuretic therapy such as Thiazides, Furosemide (INN) or frusemide (former BAN) within
             one month before screening

          -  Subjects taking over-the-counter (OTC) or prescribed phosphorous or calcium containing
             supplements

          -  Subjects testing positive for drugs of abuse
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Antoinette A. Pragalos, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Community Research</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Community Research</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45206</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 26, 2008</study_first_submitted>
  <study_first_submitted_qc>August 27, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 28, 2008</study_first_posted>
  <last_update_submitted>February 6, 2009</last_update_submitted>
  <last_update_submitted_qc>February 6, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 9, 2009</last_update_posted>
  <responsible_party>
    <name_title>Jonathan Greenberg, MD, Director Clinical Research</name_title>
    <organization>Fresenius USA Manufacturing Inc., d/b/a Fresenius Medical Care North America</organization>
  </responsible_party>
  <keyword>bioequivalence</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperphosphatemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pharmaceutical Solutions</mesh_term>
    <mesh_term>Calcium, Dietary</mesh_term>
    <mesh_term>Citric Acid</mesh_term>
    <mesh_term>Calcium acetate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

